BR112012015386B8 - composição oftálmica tópica - Google Patents

composição oftálmica tópica

Info

Publication number
BR112012015386B8
BR112012015386B8 BR112012015386A BR112012015386A BR112012015386B8 BR 112012015386 B8 BR112012015386 B8 BR 112012015386B8 BR 112012015386 A BR112012015386 A BR 112012015386A BR 112012015386 A BR112012015386 A BR 112012015386A BR 112012015386 B8 BR112012015386 B8 BR 112012015386B8
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
topical ophthalmic
ocular diseases
topical
prevention
Prior art date
Application number
BR112012015386A
Other languages
English (en)
Other versions
BR112012015386B1 (pt
BR112012015386A2 (pt
Inventor
Ponsati Obiols Berta
HERNÁNDEZ PASCUAL Cristina
FERNÁNDEZ CARNEADO Jimena
Farrera Sinfreu Josep
GÓMEZ CAMINALS Marc
SIMÓ CANONGE Rafael
Jordana I Lluch Ribera
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012015386(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of BR112012015386A2 publication Critical patent/BR112012015386A2/pt
Publication of BR112012015386B1 publication Critical patent/BR112012015386B1/pt
Publication of BR112012015386B8 publication Critical patent/BR112012015386B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

composição oftálmica tópica. trata-se de uma formulação oftálmica de peptídeos e seu uso para o tratamento e/ou prevenção local de doenças oculares, de preferência, doenças oculares do segmento posterior.
BR112012015386A 2009-12-22 2010-12-17 composição oftálmica tópica BR112012015386B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200931242A ES2362604B1 (es) 2009-12-22 2009-12-22 Formulación tópica oftálmica de péptidos.
ESP200931242 2009-12-23
PCT/EP2010/007737 WO2011076368A2 (en) 2009-12-22 2010-12-17 Topical ophthalmic peptide formulation

Publications (3)

Publication Number Publication Date
BR112012015386A2 BR112012015386A2 (pt) 2018-07-24
BR112012015386B1 BR112012015386B1 (pt) 2021-02-23
BR112012015386B8 true BR112012015386B8 (pt) 2021-05-25

Family

ID=43928893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015386A BR112012015386B8 (pt) 2009-12-22 2010-12-17 composição oftálmica tópica

Country Status (34)

Country Link
US (1) US9216208B2 (pt)
EP (1) EP2515870B1 (pt)
JP (1) JP5920928B2 (pt)
KR (1) KR101657737B1 (pt)
CN (1) CN102753153B (pt)
AR (1) AR079683A1 (pt)
AU (1) AU2010335595B2 (pt)
BR (1) BR112012015386B8 (pt)
CA (1) CA2785104C (pt)
CL (1) CL2012001737A1 (pt)
CO (1) CO6592047A2 (pt)
CY (1) CY1117854T1 (pt)
DK (1) DK2515870T3 (pt)
ES (2) ES2362604B1 (pt)
HK (1) HK1178049A1 (pt)
HR (1) HRP20160954T1 (pt)
HU (1) HUE028193T2 (pt)
IL (1) IL220584A (pt)
LT (1) LT2515870T (pt)
MX (1) MX338323B (pt)
MY (1) MY178169A (pt)
NZ (1) NZ600627A (pt)
PL (1) PL2515870T3 (pt)
PT (1) PT2515870T (pt)
RS (1) RS54953B1 (pt)
RU (1) RU2561585C2 (pt)
SG (1) SG181727A1 (pt)
SI (1) SI2515870T1 (pt)
SM (1) SMT201600277B (pt)
TW (1) TWI548416B (pt)
UA (1) UA108484C2 (pt)
UY (1) UY33153A (pt)
WO (1) WO2011076368A2 (pt)
ZA (1) ZA201204522B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2968471T1 (sl) 2013-03-01 2017-11-30 Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogo
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
MX2019008104A (es) 2017-01-31 2019-10-17 Kimberly Clark Co Composicion antibacteriana que incluye un ester del acido benzoico y metodos de inhibicion del crecimiento bacteriano mediante el uso de la misma.
EP3624829A4 (en) * 2017-05-15 2020-10-28 Sun Pharmaceutical Industries Limited OCTREOTIDE INJECTION
JP7470791B2 (ja) * 2019-11-21 2024-04-18 サムジン ファーマシューティカル カンパニー，リミテッド 眼疾患の予防または治療用点眼組成物
KR20230133595A (ko) * 2022-03-11 2023-09-19 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
EP0966271A1 (en) * 1997-11-06 1999-12-29 Orbon Corporation Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
CA2263042A1 (en) * 1999-02-25 2000-08-25 Robert W.A. Kuijpers Treatment of edema
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
AU2001283957A1 (en) * 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
EP1651136B1 (en) * 2003-07-15 2017-03-08 Evonik Corporation Method for the preparation of controlled release formulations
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
ATE553772T1 (de) * 2007-09-11 2012-05-15 Mondobiotech Lab Ag Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
ES2528409T3 (es) * 2007-10-24 2015-02-10 Camurus Ab Formulaciones de liberación controlada

Also Published As

Publication number Publication date
TWI548416B (zh) 2016-09-11
BR112012015386B1 (pt) 2021-02-23
HRP20160954T1 (hr) 2016-10-07
DK2515870T3 (en) 2016-09-05
ES2362604B1 (es) 2012-06-28
CN102753153A (zh) 2012-10-24
NZ600627A (en) 2014-08-29
ES2587828T3 (es) 2016-10-27
WO2011076368A2 (en) 2011-06-30
CL2012001737A1 (es) 2012-11-16
AU2010335595A1 (en) 2012-07-12
WO2011076368A3 (en) 2012-03-15
ZA201204522B (en) 2013-09-25
LT2515870T (lt) 2016-10-10
EP2515870B1 (en) 2016-05-25
IL220584A (en) 2016-10-31
HUE028193T2 (en) 2016-12-28
RS54953B1 (sr) 2016-11-30
PL2515870T3 (pl) 2016-11-30
UA108484C2 (en) 2015-05-12
SMT201600277B (it) 2016-11-10
JP5920928B2 (ja) 2016-05-18
UY33153A (es) 2011-06-30
SG181727A1 (en) 2012-07-30
MX338323B (es) 2016-04-12
SI2515870T1 (sl) 2016-09-30
ES2362604A1 (es) 2011-07-08
US20130210728A1 (en) 2013-08-15
IL220584A0 (en) 2012-08-30
HK1178049A1 (zh) 2013-09-06
RU2561585C2 (ru) 2015-08-27
KR20120120255A (ko) 2012-11-01
AU2010335595B2 (en) 2015-08-27
JP2013515687A (ja) 2013-05-09
RU2012126028A (ru) 2014-01-27
CY1117854T1 (el) 2017-05-17
CA2785104C (en) 2016-11-01
KR101657737B1 (ko) 2016-09-19
CO6592047A2 (es) 2013-01-02
US9216208B2 (en) 2015-12-22
MY178169A (en) 2020-10-06
AR079683A1 (es) 2012-02-15
CA2785104A1 (en) 2011-06-30
CN102753153B (zh) 2015-11-25
BR112012015386A2 (pt) 2018-07-24
PT2515870T (pt) 2016-08-29
TW201141514A (en) 2011-12-01
MX2012007282A (es) 2012-10-15
EP2515870A2 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
BR112012015386B8 (pt) composição oftálmica tópica
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
ECSP21002804A (es) Apirasas solubilizadas, métodos y usos
BR112014000795A2 (pt) uso cosmético e/ou dermatológico de compostos oligossacarídeos na prevenção e no tratamento de estrias
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112018003455A2 (pt) composição ou composição farmacêutica e uso da composição
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
BR112014016804A2 (pt) composições, métodos de uso e métodos de tratamento
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AU2014216273A8 (en) Topical ocular analgesic agents
EA202091062A1 (ru) Карбоксилхитозан
UY33788A (es) Derivados de arilsulfonamida para la prevención o el tratamiento de trastornos oftalmológicos específicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF